Landscape Capital Management L.L.C. Sells 372,640 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI)

Landscape Capital Management L.L.C. lowered its position in Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) by 87.7% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 52,085 shares of the company's stock after selling 372,640 shares during the quarter. Landscape Capital Management L.L.C. owned about 0.07% of Trevi Therapeutics worth $215,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently added to or reduced their stakes in TRVI. JPMorgan Chase & Co. lifted its holdings in Trevi Therapeutics by 220.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 100,517 shares of the company's stock valued at $336,000 after acquiring an additional 69,167 shares during the last quarter. Geode Capital Management LLC grew its position in Trevi Therapeutics by 10.2% during the third quarter. Geode Capital Management LLC now owns 1,264,166 shares of the company's stock valued at $4,223,000 after purchasing an additional 117,418 shares in the last quarter. Charles Schwab Investment Management Inc. increased its stake in shares of Trevi Therapeutics by 14.7% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 173,063 shares of the company's stock worth $713,000 after acquiring an additional 22,145 shares during the last quarter. Barclays PLC grew its stake in Trevi Therapeutics by 180.8% in the third quarter. Barclays PLC now owns 95,232 shares of the company's stock valued at $319,000 after purchasing an additional 61,317 shares in the last quarter. Finally, State Street Corp increased its holdings in Trevi Therapeutics by 5.9% in the third quarter. State Street Corp now owns 952,912 shares of the company's stock worth $3,183,000 after buying an additional 53,051 shares during the last quarter. Institutional investors own 95.76% of the company's stock.

Insider Activity at Trevi Therapeutics

In other news, insider Farrell Simon sold 81,313 shares of the firm's stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $6.75, for a total transaction of $548,862.75. Following the completion of the sale, the insider now owns 76,900 shares of the company's stock, valued at $519,075. This trade represents a 51.39 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO Jennifer L. Good sold 5,263 shares of Trevi Therapeutics stock in a transaction on Friday, March 21st. The shares were sold at an average price of $6.58, for a total transaction of $34,630.54. Following the completion of the sale, the chief executive officer now directly owns 213,313 shares of the company's stock, valued at approximately $1,403,599.54. This trade represents a 2.41 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 24.37% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the stock. Raymond James upgraded shares of Trevi Therapeutics from an "outperform" rating to a "strong-buy" rating and lifted their target price for the stock from $9.00 to $29.00 in a report on Monday, March 10th. Oppenheimer boosted their price objective on shares of Trevi Therapeutics from $12.00 to $20.00 and gave the stock an "outperform" rating in a report on Tuesday, March 11th. Needham & Company LLC reissued a "buy" rating and set a $24.00 price objective on shares of Trevi Therapeutics in a report on Tuesday, April 8th. HC Wainwright restated a "buy" rating and issued a $12.50 target price on shares of Trevi Therapeutics in a research note on Wednesday, March 19th. Finally, D. Boral Capital reissued a "buy" rating and issued a $21.00 price target on shares of Trevi Therapeutics in a report on Wednesday, March 19th. Seven analysts have rated the stock with a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat, Trevi Therapeutics currently has an average rating of "Buy" and an average target price of $17.56.

Trevi Therapeutics Stock Up 2.5 %

Shares of Trevi Therapeutics stock traded up $0.14 during trading on Monday, reaching $5.70. The company's stock had a trading volume of 143,549 shares, compared to its average volume of 1,079,142. The business's 50-day moving average price is $5.30 and its 200-day moving average price is $4.08. Trevi Therapeutics, Inc. has a 52 week low of $2.30 and a 52 week high of $7.39. The firm has a market cap of $551.09 million, a PE ratio of -12.95 and a beta of 0.41.

Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last issued its quarterly earnings results on Tuesday, March 18th. The company reported ($0.11) earnings per share for the quarter, topping analysts' consensus estimates of ($0.12) by $0.01. Equities analysts predict that Trevi Therapeutics, Inc. will post -0.49 earnings per share for the current year.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.